论文部分内容阅读
目的探讨孟鲁司特联合沙美特罗替卡松治疗支气管哮喘患者的临床疗效。方法选取2015年1月至2016年2月于沈阳市红十字会医院就诊的108例支气管哮喘患者作为研究对象,按照随机数字表法将其分为观察组与对照组,各54例。对照组患者给予孟鲁司特,观察组患者在对照组基础上采用沙美特罗替卡松进行治疗,比较两组患者临床治疗效果、治疗前后症状评分及肺功能、不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(χ2=6.20,P=0.0128);治疗后,观察组患者的日间哮喘、夜间哮喘评分均明显低于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组患者的最大呼气流量(PEF)、第1秒钟用力呼气容积(FEV1)及FEV1/用力肺活量(FVC)%均明显高于对照组,差异均有统计学意义(均P<0.05)。结论孟鲁司特联合沙美特罗替卡松治疗支气管哮喘效果显著,不良反应少,可有效改善患者临床症状,提高肺功能。
Objective To investigate the clinical efficacy of montelukast combined with salmeterol and fluticasone in patients with bronchial asthma. Methods A total of 108 patients with bronchial asthma from January 2015 to February 2016 in Shenyang Red Cross Hospital were enrolled in this study. According to the random number table, they were divided into observation group and control group, 54 cases each. Patients in the control group were treated with montelukast. The patients in the observation group were treated with salmeterol and fluticasone on the basis of the control group. The clinical effects, symptom scores, pulmonary function and adverse reactions in both groups were compared. Results The total effective rate of observation group was significantly higher than that of the control group (χ2 = 6.20, P = 0.0128). After treatment, the daytime asthma and nighttime asthma scores of the observation group were significantly lower than those of the control group (P <0.05). After treatment, the maximum expiratory flow (PEF), FEV1 and FEV1 / FVC of the observation group were significantly higher than those of the control group Significantly higher than the control group, the differences were statistically significant (P <0.05). Conclusion Montelukast combined with salmeterol and fluticasone treatment of bronchial asthma significantly, with fewer adverse reactions, can effectively improve the clinical symptoms and improve lung function.